首页> 外文OA文献 >Preparation and characterization of starch-poly-epsilon-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications
【2h】

Preparation and characterization of starch-poly-epsilon-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications

机译:包含生物活性剂的淀粉-聚-ε-己内酯微粒的制备和表征,用于药物输送和组织工程应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

One limitation associated with the delivery of bioactive agents concerns the short half-life of these molecules when administered intravenously,which results in their loss from the desired site. Incorporation of bioactive agents into depot vehicles provides a means toincrease their persistence at the disease site. Major issues are involved in the development of a proper carrier system able to deliverthe correct drug, at the desired dose, place and time. In this work, starch-poly-e-caprolactone (SPCL) microparticles were developedfor use in drug delivery and tissue engineering (TE) applications. SPCL microparticles were prepared by using an emulsion solventextraction/evaporation technique, which was demonstrated to be a successful procedure to obtain particles with a spherical shape (particlesize between 5 and 900 lm) and exhibiting different surface morphologies. Their chemical structure was confirmed by Fourier transforminfrared spectroscopy. To evaluate the potential of the developed microparticles as a drug delivery system, dexamethasone (DEX)was used as model drug. DEX, a well-known component of osteogenic differentiation media, was entrapped into SPCL microparticles atdifferent percentages up to 93%. The encapsulation efficiency was found to be dependent on the polymer concentration and drug-to-polymerratio. The initial DEX release seems to be governed mainly by diffusion, and it is expected that the remaining DEX will be releasedwhen the polymeric matrix starts to degrade. In this work it was demonstrated that SPCL microparticles containing DEX can be successfullyprepared and that these microparticular systems seem to be quite promising for controlled release applications, namely as carriersof important differentiation agents in TE.
机译:与生物活性剂的输送有关的一个局限性是当静脉内给药时这些分子的半衰期短,这导致它们从所需部位损失。将生物活性剂掺入仓库车辆中提供了增加其在疾病部位的持久性的手段。主要问题涉及开发合适的载体系统,该系统能够在所需的剂量,位置和时间递送正确的药物。在这项工作中,开发了淀粉-聚-ε-己内酯(SPCL)微粒,用于药物递送和组织工程(TE)应用。通过使用乳液溶剂萃取/蒸发技术制备SPCL微粒,这被证明是获得球形(粒径在5到900 lm之间)并表现出不同表面形态的颗粒的成功方法。通过傅立叶变换红外光谱法证实了它们的化学结构。为了评估已开发的微粒作为药物递送系统的潜力,地塞米松(DEX)被用作模型药物。 DEX是成骨分化培养基的一种众所周知的成分,以高达93%的不同百分比被包埋在SPCL微粒中。发现包封效率取决于聚合物浓度和药物与聚合物的比率。最初的DEX释放似乎主要由扩散决定,并且可以预期,当聚合物基质开始降解时,其余的DEX将会释放。在这项工作中,证明了可以成功制备含DEX的SPCL微粒,并且这些微粒系统对于控释应用(即作为TE中重要的分化剂的载体)似乎很有希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号